-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 L/gnq1M3rizWEFYIwT0I69dY4IP08Y9XRHfbm3q5ajXgNc5w1w0rBsvaeem3qEXv
 RJgxQUcOJGEQshlJItBLzw==

<SEC-DOCUMENT>0001412292-07-000004.txt : 20071002
<SEC-HEADER>0001412292-07-000004.hdr.sgml : 20071002
<ACCEPTANCE-DATETIME>20071002114027
ACCESSION NUMBER:		0001412292-07-000004
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20071001
FILED AS OF DATE:		20071002
DATE AS OF CHANGE:		20071002

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PHARMACEUTICAL PRODUCT DEVELOPMENT INC
		CENTRAL INDEX KEY:			0001003124
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				561640186
		STATE OF INCORPORATION:			NC
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		929 NORTH FRONT STREET
		CITY:			WILMINGTON
		STATE:			NC
		ZIP:			28401
		BUSINESS PHONE:		9102510081

	MAIL ADDRESS:	
		STREET 1:		929 NORTH FRONT STREET
		CITY:			WILMINGTON
		STATE:			NC
		ZIP:			28401

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Darazsdi Daniel G
		CENTRAL INDEX KEY:			0001412292

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27570
		FILM NUMBER:		071148169

	BUSINESS ADDRESS:	
		BUSINESS PHONE:		910-251-0081

	MAIL ADDRESS:	
		STREET 1:		C/O PHARMACEUTICAL PRODUCT DEVELOPMENT
		STREET 2:		929 NORTH FRONT STREET
		CITY:			WILMINGTON
		STATE:			NC
		ZIP:			28401
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>edgar.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0202</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2007-10-01</periodOfReport>

    <noSecuritiesOwned>1</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001003124</issuerCik>
        <issuerName>PHARMACEUTICAL PRODUCT DEVELOPMENT INC</issuerName>
        <issuerTradingSymbol>PPDI</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001412292</rptOwnerCik>
            <rptOwnerName>Darazsdi Daniel G</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>929 NORTH FRONT STREET</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>WILMINGTON</rptOwnerCity>
            <rptOwnerState>NC</rptOwnerState>
            <rptOwnerZipCode>28401</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Financial Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <footnotes></footnotes>

    <remarks>No securities are beneficially owned.</remarks>

    <ownerSignature>
        <signatureName>Lisa C. Noecker attorney-in-fact for Daniel G. Darazsdi</signatureName>
        <signatureDate>2007-10-02</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----